Bernhard Hemmer

List of Publications by Year
in descending order

401 papers	37,960 citations	3159 92 h-index	3830 178 g-index
439 all docs	439 docs citations	439 times ranked	34731 citing authors

#	Article	IF	Citations
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
2	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
3	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
4	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	21.4	1,213
5	Multiple sclerosis. Lancet, The, 2018, 391, 1622-1636.	13.7	1,204
6	An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. NeuroImage, 2012, 59, 3774-3783.	4.2	972
7	Stress doses of hydrocortisone reverse hyperdynamic septic shock. Critical Care Medicine, 1999, 27, 723-732.	0.9	941
8	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	12.6	710
9	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology, 2009, 73, 1914-1922.	1.1	653
10	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation, 2012, 9, 14.	7.2	593
11	New concepts in the immunopathogenesis of multiple sclerosis. Nature Reviews Neuroscience, 2002, 3, 291-301.	10.2	517
12	Intrathecal pathogenic antiâ€“aquaporinâ€4 antibodies in early neuromyelitis optica. Annals of Neurology, 2009, 66, 617-629.	5.3	516
13	Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain, 2006, 129, 200-211.	7.6	485
14	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
15	Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurology, The, 2015, 14, 406-419.	10.2	455
16	TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nature Immunology, 2003, 4, 248-254.	14.5	426
17	Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of Neurology, 2006, 59, 743-747.	5.3	414
18	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	10.2	397

#	Article	IF	Citations
19	EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology, 2010, 17, 1019-1032.	3.3	376
20	Acute Disseminated Encephalomyelitis. Archives of Neurology, 2005, 62, 1673.	4.5	348
21	Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain, 2005, 128, 1667-1676.	7.6	331
22	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology, 2016, 79, 206-216.	5.3	315
23	Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 115-123.	27.0	314
24	Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class IIâ€“restricted T Cell Clone. Journal of Experimental Medicine, 1997, 185, 1651-1660.	8.5	313
25	Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113.	21.4	312
26	Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nature Immunology, 2017, 18, 74-85.	14.5	311
27	Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Annals of Neurology, 2009, 66, 833-842.	5.3	283
28	Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1383.	4.5	271
29	Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology, 2011, 76, 1310-1315.	1.1	270
30	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	10.2	261
31	Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. Journal of Clinical Investigation, 2005, 115, 1352-1360.	8.2	248
32	Î³Î´ T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism. Immunity, 2010, 33, 351-363.	14.3	246
33	Th17 lymphocytes traffic to the central nervous system independently of Î±4 integrin expression during EAE. Journal of Experimental Medicine, 2011, 208, 2465-2476.	8.5	241
34	Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain, 2002, 125, 538-550.	7.6	235
35	Immunopathogenesis and immunotherapy of multiple sclerosis. Nature Clinical Practice Neurology, 2006, 2, 201-211.	2.5	224
36	Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LCâ€“MS/MS. Nature Communications, 2020, 11, 157.	12.8	218

#	Article	IF	Citations
37	Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nature Medicine, 1999, 5, 1375-1382.	30.7	216
38	Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19057-19062.	7.1	213
39	Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain, 2001, 124, 2169-2176.	7.6	210
40	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurology, The, 2013, 12, 756-767.	10.2	205
41	A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology, 2005, 58, 50-57.	5.3	203
42	Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 822-827.	1.9	198
43	A point mutation in PTPRC is associated with the development of multiple sclerosis. Nature Genetics, 2000, 26, 495-499.	21.4	197
44	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
45	CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. Journal of Neuroinflammation, 2012, 9, 93.	7.2	190
46	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology, The, 2010, 9, 740-750.	10.2	188
47	Advances in understanding and treatment of immuneâ€mediated disorders of the peripheral nervous system. Muscle and Nerve, 2004, 30, 131-156.	2.2	185
48	Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Archives of Neurology, 2008, 65, 1596.	4.5	179
49	Spatiotemporal Reconfiguration of Large-Scale Brain Functional Networks during Propofol-Induced Loss of Consciousness. Journal of Neuroscience, 2012, 32, 12832-12840.	3.6	175
50	The increasing incidence and prevalence of female multiple sclerosisâ€”A critical analysis of potential environmental factors. Autoimmunity Reviews, 2011, 10, 495-502.	5.8	174
51	Apheresis therapies for NMOSD attacks. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e504.	6.0	173
52	Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology, 2010, 74, 1127-1135.	1.1	172
53	Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. American Journal of Human Genetics, 2013, 92, 854-865.	6.2	164
54	Mitochondrial membrane protein associated neurodegenration: A novel variant of neurodegeneration with brain iron accumulation. Movement Disorders, 2013, 28, 224-227.	3.9	162

#	Article	IF	Citations
55	Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. Journal of Clinical Investigation, 2005, 115, 1352-1360.	8.2	154
56	Simultaneous Electroencephalographic and Functional Magnetic Resonance Imaging Indicate Impaired Cortical Topâ€“Down Processing in Association with Anesthetic-induced Unconsciousness. Anesthesiology, 2013, 119, 1031-1042.	2.5	153
57	Human antibodies against amyloid Î² peptide: A potential treatment for Alzheimer's disease. Annals of Neurology, 2002, 52, 253-256.	5.3	152
58	<scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 2018, 25, 215-237.	3.3	147
59	DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. Nature Communications, 2018, 9, 2397.	12.8	147
60	Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology, 2011, 76, 1214-1221.	1.1	146
61	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
62	Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Trends in Immunology, 1998, 19, 163-168.	7.5	133
63	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809.	3.0	133
64	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678.	10.3	133
65	B lymphocytes in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e104.	6.0	132
66	Escalating immunotherapy of multiple sclerosis. Journal of Neurology, 2004, 251, 1329-1339.	3.6	129
67	Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology, 2009, 72, 396-401.	1.1	128
68	Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. Journal of the Neurological Sciences, 2020, 418, 117090.	0.6	125
69	Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 1620-3.	4.5	124
70	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647.	1.9	123
71	Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2018, 90, e1815-e1821.	1.1	123
72	The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. Journal of Autoimmunity, 2010, 34, 371-379.	6.5	121

#	Article	IF	Citations
73	Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. Journal of Immunology, 1998, 160, 5807-14.	0.8	119
74	Pathogenesis of multiple sclerosis: an update on immunology. Current Opinion in Neurology, 2002, 15, 227-231.	3.6	116
75	Acute disseminated encephalomyelitis: an acute hit against the brain. Current Opinion in Neurology, 2007, 20, 247-254.	3.6	116
76	CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. Journal of Neuroimmunology, 2007, 190, 72-79.	2.3	115
77	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
78	HLA-DRB1âˆ—0401 and HLA-DRB1âˆ—0408 Are Strongly Associated with the Development of Antibodies against Interferon-Î² Therapy in Multiple Sclerosis. American Journal of Human Genetics, 2008, 83, 219-227.	6.2	114
79	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
80	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology, 2016, 87, 978-987.	1.1	109
81	Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Research, 2009, 86, 82-88.	1.6	108
82	Characterizing the Mechanisms of Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1345.	4.5	105
83	Natalizumab and Progressive Multifocal Leukoencephalopathy. Archives of Neurology, 2010, 67, 923-30.	4.5	105
84	Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of Disease, 2009, 35, 117-127.	4.4	104
85	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629.	5.3	104
86	Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 224-234.	3.0	104
87	Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. Journal of Immunology, 1998, 160, 3631-6.	0.8	103
88	Cortical pathology in multiple sclerosis detected by the <scp>T</scp>1/<scp>T</scp>2â€weighted ratio from routine magnetic resonance imaging. Annals of Neurology, 2017, 82, 519-529.	5.3	102
89	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
90	Molecular mimicry and multiple sclerosis: Degenerate T-cell recognition and the induction of autoimmunity. Annals of Neurology, 1999, 45, 559-567.	5.3	98

#	Article	IF	Citations
91	Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. Journal of Clinical Investigation, 2006, 116, 1037-1044.	8.2	98
92	Combinatorial Peptide Libraries and Biometric Score Matrices Permit the Quantitative Analysis of Specific and Degenerate Interactions Between Clonotypic TCR and MHC Peptide Ligands. Journal of Immunology, 2001, 167, 2130-2141.	0.8	97
93	Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87â€“99). European Journal of Immunology, 1996, 26, 2624-2634.	2.9	96
94	The role of antibodies in multiple sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 239-245.	3.8	96
95	TNF-alpha induced NFÎºB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine, 2012, 57, 269-275.	3.2	96
96	Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. Journal of Neuroinflammation, 2019, 16, 219.	7.2	96
97	Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain, 2016, 139, 2855-2863.	7.6	95
98	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 2013, 19, 1533-1538.	3.0	92
99	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2016, 73, 1089.	9.0	92
100	Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity. Journal of Neurology, 2016, 263, 1495-1502.	3.6	91
101	IL-27 and IL-12 oppose pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1. Nature Communications, 2014, 5, 3770.	12.8	90
102	Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events. Journal of Immunology, 1999, 162, 2073-80.	0.8	88
103	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
104	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86
105	MRI of spinal cord and brain lesions in subacute combined degeneration. Neuroradiology, 1998, 40, 716-719.	2.2	82
106	Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. Journal of Neuroimmunology, 2010, 219, 1-7.	2.3	82
107	Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1201-8.	4.5	82
108	Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity. Nature Immunology, 2018, 19, 1341-1351.	14.5	82

#	Article	IF	Citations
109	Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. NeuroImage, 2016, 142, 188-197.	4.2	81
110	Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology, 2009, 66, 403-406.	5.3	78
111	Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurology, The, 2005, 4, 403-412.	10.2	77
112	The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. International Journal of Neuropsychopharmacology, 2009, 12, 525.	2.1	77
113	EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. European Journal of Human Genetics, 2011, 19, 465-471.	2.8	74
114	Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination. Multiple Sclerosis Journal, 2016, 22, 893-900.	3.0	74
115	EFNS guidelines on diseaseâ€specific CSF investigations. European Journal of Neurology, 2009, 16, 760.	3.3	73
116	NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Experimental Neurology, 2008, 211, 370-377.	4.1	72
117	Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. JAMA Neurology, 2018, 75, 1071.	9.0	72
118	Minimal peptide length requirements for CD4+ T cell clonesâ€"implications for molecular mimicry and T cell survival. International Immunology, 2000, 12, 375-383.	4.0	70
119	IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity, 2010, 11, 397-405.	4.1	70
120	The Immune Response at Onset and During Recovery From Borrelia burgdorferi Meningoradiculitis. Archives of Neurology, 2003, 60, 849.	4.5	69
121	Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. Journal of Neuroimmunology, 2010, 227, 162-166.	2.3	69
122	Enriched CD161^{high}CCR6⁺Î³Î´ T Cells in the Cerebrospinal Fluid of Patients With Multiple Sclerosis. JAMA Neurology, 2013, 70, 345.	9.0	69
123	Dimethyl fumarate in relapsingâ€"remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics, 2015, 15, 339-346.	2.8	69
124	Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. Journal of Neuroinflammation, 2011, 8, 146.	7.2	68
125	Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology, 2014, 175, 397-407.	2.6	68
126	Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. Journal of Neurology, 2014, 261, 130-143.	3.6	67

#	Article	IF	Citations
127	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	6.1	67
128	Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab. Archives of Neurology, 2009, 66, 1016-20.	4.5	66
129	Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain, Behavior, and Immunity, 2011, 25, 423-428.	4.1	66
130	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 681-686.	1.9	66
131	Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. Journal of Immunology, 1997, 158, 2756-61.	0.8	66
132	Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy. Archives of Neurology, 2007, 64, 169.	4.5	65
133	A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nature Communications, 2019, 10, 2236.	12.8	65
134	Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency. Journal of Immunology, 2000, 164, 861-871.	0.8	64
135	Toward the development of rational therapies in multiple sclerosis: what is on the horizon?. Annals of Neurology, 2007, 62, 314-326.	5.3	64
136	Treatment of MOG antibody associated disorders: results of an international survey. Journal of Neurology, 2020, 267, 3565-3577.	3.6	64
137	Disease-Modifying Agents for Multiple Sclerosis. Drugs, 2008, 68, 2445-2468.	10.9	63
138	Molecular Mimicry and Antigen-Specific T Cell Responses in Multiple Sclerosis and Chronic CNS Lyme Disease. Journal of Autoimmunity, 2001, 16, 187-192.	6.5	61
139	Active Immunization with Amyloid-Î² 1â€“42 Impairs Memory Performance through TLR2/4-Dependent Activation of the Innate Immune System. Journal of Immunology, 2010, 185, 6338-6347.	0.8	61
140	Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Journal of Neuroimmunology, 2005, 168, 128-137.	2.3	60
141	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1092-1103.	3.0	60
142	Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging. NeuroImage: Clinical, 2019, 23, 101849.	2.7	60
143	Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. Journal of Neuroimmunology, 1998, 87, 203-209.	2.3	59
144	The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Experimental Neurology, 2015, 265, 8-21.	4.1	59

#	Article	IF	Citations
145	T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. Journal of Neuroimmunology, 1997, 77, 195-203.	2.3	58
146	Acyclovir resistance in herpes simplex encephalitis. Annals of Neurology, 2010, 67, 830-833.	5.3	58
147	The neuropathology of fatal encephalomyelitis in human Borna virus infection. Acta Neuropathologica, 2019, 138, 653-665.	7.7	57
148	Impact of HMG-CoA reductase inhibition on brain pathology. Trends in Pharmacological Sciences, 2007, 28, 342-349.	8.7	56
149	Accumulation of class switched IgDâ^'IgMâ^' memory B cells in the cerebrospinal fluid during neuroinflammation. Journal of Neuroimmunology, 2006, 180, 33-39.	2.3	55
150	Boxing. Deutsches Ärzteblatt International, 2010, 107, 835-9.	0.9	55
151	Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology, 2010, 74, 1711-1715.	1.1	54
152	Functional Characterization of Aquaporin-4 Specific T Cells: Towards a Model for Neuromyelitis Optica. PLoS ONE, 2011, 6, e16083.	2.5	54
153	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643.	7.6	54
154	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	6.0	54
155	DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. PLoS Computational Biology, 2020, 16, e1007616.	3.2	54
156	Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Annals of Neurology, 2011, 70, 520-520.	5.3	53
157	CNS Aquaporinâ€4â€specific B cells connect with multiple Bâ€cell compartments in neuromyelitis optica spectrum disorder. Annals of Clinical and Translational Neurology, 2017, 4, 369-380.	3.7	53
158	Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients. PLoS ONE, 2017, 12, e0179590.	2.5	53
159	Varicella zoster virus is not a diseaseâ€relevant antigen in multiple sclerosis. Annals of Neurology, 2009, 65, 474-479.	5.3	52
160	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Multiple Sclerosis International, 2011, 2011, 1-9.	0.8	52
161	Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. Journal of Immunology, 1997, 158, 3746-52.	0.8	52
162	Influence of the HLA-DRB1 Genotype on Antibody Development to Interferon Beta in Multiple Sclerosis. Archives of Neurology, 2011, 68, 480.	4.5	51

#	Article	IF	Citations
163	High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: Implications for the initiation of autoimmune response in multiple sclerosis. Journal of Neuroimmunology, 2005, 169, 31-38.	2.3	50
164	Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 875-884.	3.0	50
165	White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Multiple Sclerosis Journal, 2013, 19, 1485-1492.	3.0	49
166	JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants. PLoS Pathogens, 2014, 10, e1004084.	4.7	49
167	Neutralising antibodies to interferon Î² in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837.	3.6	48
168	Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. Current Pharmaceutical Design, 2012, 18, 209-219.	1.9	48
169	The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. Journal of Neuroinflammation, 2015, 12, 19.	7.2	48
170	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurology, 2019, 76, 841.	9.0	48
171	Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. Journal of Immunology, 1999, 163, 6424-34.	0.8	48
172	Effect of minocycline in experimental autoimmune encephalomyelitis. Annals of Neurology, 2002, 52, 689-690.	5.3	47
173	Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain, 2007, 130, 2186-2198.	7.6	47
174	Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology, 2011, 258, 1747-1762.	3.6	47
175	Neuromyelitis optica following human papillomavirus vaccination. Neurology, 2012, 79, 285-287.	1.1	47
176	Prevalence of neuropathic pain in early multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1224-1230.	3.0	47
177	Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis. Journal of Autoimmunity, 2015, 56, 34-44.	6.5	46
178	Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis. Radiology, 2019, 291, 429-435.	7.3	46
179	Monocyte NOTCH2 expression predicts IFN-Î² immunogenicity in multiple sclerosis patients. JCI Insight, 2018, 3, .	5.0	46
180	Effects of interferon-Î² on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-Î² treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 166-176.	3.0	45

#	Article	IF	Citations
181	Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology, 2014, 82, 470-473.	1.1	45
182	In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis opticaâ€related pathology. Annals of Neurology, 2016, 79, 794-805.	5.3	45
183	PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?. Neurology, 2016, 87, 440-441.	1.1	45
184	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. Neurology, 2020, 94, e1950-e1960.	1.1	45
185	Cooperation of B Cells and T Cells in the Pathogenesis of Multiple Sclerosis. Results and Problems in Cell Differentiation, 2009, 51, 115-126.	0.7	44
186	Lack of association with TorsinA haplotype in German patients with sporadic dystonia. Neurology, 2006, 66, 951-952.	1.1	43
187	Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology, 2007, 20, 286-293.	3.6	43
188	Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-Î² therapy in multiple sclerosis patients. Pharmacogenomics Journal, 2012, 12, 238-245.	2.0	43
189	Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor VÎ² analysis. Journal of Immunological Methods, 2000, 246, 131-143.	1.4	42
190	Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses. Frontiers in Immunology, 2020, 11, 606338.	4.8	42
191	Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). Journal of Neuroscience Research, 1996, 45, 852-862.	2.9	41
192	Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist â€" A putative role for substance P in CNS inflammation. Journal of Neuroimmunology, 2006, 179, 1-8.	2.3	41
193	Clonal expansions of CD4+ Bâ€„helper T cells in autoimmune myasthenia gravis. European Journal of Immunology, 2007, 37, 849-863.	2.9	41
194	Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83.	10.9	41
195	MRI Plaque Imaging Detects Carotid Plaques with a High Risk for Future Cerebrovascular Events in Asymptomatic Patients. PLoS ONE, 2013, 8, e67927.	2.5	41
196	To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 271-279.	3.0	41
197	Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Annals of Neurology, 2014, 75, 810-828.	5.3	41
198	Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype. Neurology, 1997, 49, 1116-1126.	1.1	40

#	Article	IF	Citations
199	Persistence of Immunopathological and Radiological Traits in Multiple Sclerosis. Archives of Neurology, 2008, 65, 1527.	4.5	40
200	Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?. Neurology, 2012, 78, 928-930.	1.1	40
201	From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. Current Neuropharmacology, 2017, 15, 874-891.	2.9	40
202	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
203	Multiple Sclerosis - A Coordinated Immune Attack Across the Blood Brain Barrier. Current Neurovascular Research, 2004, 1, 141-150.	1.1	38
204	Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2009, 66, 259-61.	4.5	38
205	MRI plaque imaging reveals high-risk carotid plaques especially in diabetic patients irrespective of the degree of stenosis. BMC Medical Imaging, 2010, 10, 27.	2.7	38
206	Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Annals of Neurology, 2013, 73, 86-94.	5.3	38
207	Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis. JAMA Neurology, 2017, 74, 847.	9.0	38
208	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
209	Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis. Archives of Neurology, 2009, 66, 1216.	4.5	37
210	Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1454-1461.	3.0	37
211	Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms. Multiple Sclerosis Journal, 2022, 28, 1020-1027.	3.0	37
212	The radiologically isolated syndrome: take action when the unexpected is uncovered?. Journal of Neurology, 2010, 257, 1602-1611.	3.6	36
213	Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain, 2010, 133, 375-388.	7.6	36
214	¹⁸F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions. Journal of Nuclear Medicine, 2012, 53, 1269-1276.	5.0	36
215	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36
216	Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters. Multiple Sclerosis Journal, 2018, 24, 1115-1125.	3.0	36

#	Article	IF	Citations
217	A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics, 2002, 54, 158-163.	2.4	35
218	EASY-HIT: HIV Full-Replication Technology for Broad Discovery of Multiple Classes of HIV Inhibitors. Antimicrobial Agents and Chemotherapy, 2010, 54, 5257-5268.	3.2	35
219	Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. Journal of Immunology, 1997, 159, 1520-9.	0.8	35
220	Multiple sclerosis â€“ novel insights and new therapeutic strategies. Current Opinion in Neurology, 2005, 18, 211-220.	3.6	34
221	CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opinion on Biological Therapy, 2019, 19, 829-843.	3.1	34
222	Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. Nature Immunology, 2021, 22, 880-892.	14.5	34
223	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12, e0170395.	2.5	34
224	A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015. Frontiers in Neurology, 2018, 9, 871.	2.4	33
225	Artificial intelligence extension of the OSCARâ€¦B criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	3.7	33
226	Current and Future Therapies Targeting the Immune System in Multiple Sclerosis. Current Pharmaceutical Biotechnology, 2014, 15, 276-296.	1.6	33
227	A large case-control study on vaccination as risk factor for multiple sclerosis. Neurology, 2019, 93, e908-e916.	1.1	31
228	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Multiple Sclerosis Journal, 2022, 28, 132-138.	3.0	31
229	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
230	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology, 2014, 83, 1210-1216.	1.1	30
231	B cell-directed therapies in multiple sclerosis. Neurodegenerative Disease Management, 2016, 6, 37-47.	2.2	30
232	Recommendations for the Calculation of the Total Disturbing Return Current From Electric Traction Vehicles. IEEE Transactions on Power Delivery, 2004, 19, 1190-1197.	4.3	29
233	Viral load determines the Bâ€cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Annals of Neurology, 2007, 62, 458-467.	5.3	29
234	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain, 2020, 161, 787-796.	4.2	29

#	Article	IF	Citations
235	New immunopathologic insights into multiple sclerosis. Current Neurology and Neuroscience Reports, 2003, 3, 246-255.	4.2	27
236	Clonal Accumulation of Activated CD8+T Cells in the Central Nervous System during the Early Phase of Neuroborreliosis. Journal of Infectious Diseases, 2003, 187, 963-973.	4.0	27
237	Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. Multiple Sclerosis Journal, 2012, 18, 1045-1049.	3.0	27
238	Restless legs syndrome after a borrelia-induced myelitis. Movement Disorders, 1995, 10, 521-522.	3.9	26
239	High-sensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. Journal of Neurology, 2009, 256, 783-791.	3.6	26
240	The Combination of Interferonâ€Beta and HMGâ€CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?. CNS Neuroscience and Therapeutics, 2010, 16, 362-373.	3.9	26
241	The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. Acta Neuropathologica, 2016, 132, 413-431.	7.7	26
242	COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	26
243	Impact of the Asp299Gly polymorphism in the toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosis. Journal of Neuroimmunology, 2005, 165, 161-165.	2.3	25
244	Î±4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathologica Communications, 2014, 2, 27.	5.2	25
245	The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells. Chemical Biology and Drug Design, 1998, 52, 338-345.	1.1	24
246	Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1189-1192.	3.0	24
247	More CLEC16A gene variants associated with multiple sclerosis. Acta Neurologica Scandinavica, 2011, 123, 400-406.	2.1	24
248	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	8.1	24
249	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology, 2019, 266, 386-397.	3.6	24
250	Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2022, 28, 522-531.	3.0	24
251	Repetitive Pertussis Toxin Promotes Development of Regulatory T Cells and Prevents Central Nervous System Autoimmune Disease. PLoS ONE, 2010, 5, e16009.	2.5	24
252	Lesion patterns in patients with cryptogenic stroke with and without rightâ€toâ€leftâ€shunt. European Journal of Neurology, 2009, 16, 1077-1082.	3.3	23

#	Article	IF	Citations
253	Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta. Archives of Neurology, 2010, 67, 1095-101.	4.5	23
254	Intrathecal antiâ€•<scp>CD</scp> 20 efficiently depletes meningeal B cells in <scp>CNS</scp> autoimmunity. Annals of Clinical and Translational Neurology, 2014, 1, 490-496.	3.7	23
255	Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy. Journal of Neurology, 2020, 267, 2307-2318.	3.6	23
256	From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology, 2022, 18, 559-572.	10.1	23
257	Central nervous system infections â€“ a potential complication of systemic immunotherapy. Current Opinion in Neurology, 2006, 19, 271-276.	3.6	22
258	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	2.3	22
259	A call for a global COVID-19 Neuro Research Coalition. Lancet Neurology, The, 2020, 19, 482-484.	10.2	22
260	Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. Multiple Sclerosis Journal, 2016, 22, 1192-1201.	3.0	21
261	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
262	Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis. European Journal of Neurology, 2020, 27, 2217-2224.	3.3	21
263	The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. Neurology, 2022, 99, .	1.1	21
264	Gene expression profiles derived from single cells in human postmortem brain. Brain Research Protocols, 2004, 13, 18-25.	1.6	20
265	Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-Î², glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. PLoS ONE, 2020, 15, e0235449.	2.5	20
266	Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics, 2021, 18, 364-377.	4.4	20
267	Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis. Neurology, 2021, 96, .	1.1	20
268	Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110227.	1.0	20
269	High throughput analysis of TCR-Î² rearrangement and gene expression in single T cells. Laboratory Investigation, 2006, 86, 314-321.	3.7	19
270	Dynamics of Intracranial Venous Flow Patterns in Patients with Idiopathic Intracranial Hypertension. European Neurology, 2011, 66, 334-338.	1.4	19

#	Article	IF	Citations
271	Degeneracy in T-cell antigen recognition â€“ implications for the pathogenesis of autoimmune diseases. Journal of Neuroimmunology, 2000, 107, 148-153.	2.3	18
272	Immunosuppressive Treatment of Ocular Myasthenia Gravis. BioDrugs, 2001, 15, 369-378.	4.6	18
273	Prognostic value of the ABCD2score beyond short-term follow-up after transient ischemic attack (TIA) - a cohort study. BMC Neurology, 2010, 10, 50.	1.8	18
274	Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. European Journal of Immunology, 2013, 43, 2078-2088.	2.9	18
275	Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2014, 20, 882-888.	3.0	18
276	Predictive value of transcranial evoked potentials during mechanical endovascular therapy for acute ischaemic stroke: a feasibility study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 598-603.	1.9	18
277	Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876719.	1.0	18
278	CSF parameters associated with early MRI activity in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e573.	6.0	18
279	CD45 Isoform Expression in Autoimmune Myasthenia Gravis. Autoimmunity, 2003, 36, 117-121.	2.6	17
280	Myoclonusâ€dystonia in 18p deletion syndrome. Movement Disorders, 2011, 26, 560-561.	3.9	17
281	Update on immunopathogenesis and immunotherapy in multiple sclerosis. ImmunoTargets and Therapy, 2013, 2, 21.	5.8	17
282	Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillainâ€“BarrÃ© syndrome. Journal of Neurology, 2016, 263, 2105-2113.	3.6	17
283	The spectrum of aseptic central nervous system infections in southern Germany â€“ demographic, clinical and laboratory findings. European Journal of Neurology, 2017, 24, 1062-1070.	3.3	17
284	Human T lymphocytes specific for the immunodominant 83-99 epitope of myelin basic protein: Recognition of golli MBP HOG 7. , 1996, 45, 820-828.		16
285	Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathologica, 2004, 107, 575-577.	7.7	16
286	Patent foramen ovale is not associated with an increased risk of stroke recurrence. European Journal of Neurology, 2010, 17, 1339-1345.	3.3	16
287	Pearls & Oy-sters: Cerebral HSV-2 vasculitis presenting as hemorrhagic stroke followed by multifocal ischemia. Neurology, 2012, 78, e12-e15.	1.1	16
288	Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Review of Clinical Immunology, 2015, 11, 93-108.	3.0	16

#	Article	IF	Citations
289	Case Series: Acute Hemorrhagic Encephalomyelitis After SARS-CoV-2 Vaccination. Frontiers in Neurology, 2021, 12, 820049.	2.4	16
290	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
291	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International, 2010, 57, 662-667.	3.8	15
292	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608.	1.3	15
293	Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
294	Decrypting the spectrum of antigen-specific T-cell responses: the avidity repertoire of MBP-specific T-cells. , 2000, 59, 86-93.		14
295	New approaches to dissect degeneracy and specificity in T cell antigen recognition. Journal of Molecular Medicine, 2001, 79, 358-367.	3.9	14
296	HIVâ€“hepatitis C virus co-infection is associated with decreased plasmatic IL-7 levels. Aids, 2007, 21, 253-255.	2.2	14
297	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. Neuropsychiatric Disease and Treatment, 2013, 9, 1339.	2.2	14
298	Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	14
299	Viral Pathogens in Multiple Sclerosis. Archives of Neurology, 2004, 61, 1500.	4.5	13
300	Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clinical Immunology, 2008, 128, 306-313.	3.2	13
301	Anti-JC-virus antibody prevalence in a German MS cohort. Multiple Sclerosis Journal, 2012, 18, 1054-1055.	3.0	13
302	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2013, 70, 248.	9.0	13
303	Biomarkers of treatment response in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 165-172.	2.8	13
304	Isolation, Culture and Functional Characterization of Glia and Endothelial Cells From Adult Pig Brain. Frontiers in Cellular Neuroscience, 2019, 13, 333.	3.7	13
305	Code Stroke Patient Referral by Emergency Medical Services During the Public COVID-19 Pandemic Lockdown. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105175.	1.6	13
306	Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13

#	Article	IF	Citations
307	Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13
308	Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis. Tissue Antigens, 2004, 64, 70-73.	1.0	12
309	Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. Journal of Neurology, 2005, 252, v30-v37.	3.6	12
310	The Value of the Serum Neurofilament Protein Heavy Chain as a Biomarker for Peri-operative Brain Injury After Carotid Endarterectomy. Neurochemical Research, 2009, 34, 1969-1974.	3.3	12
311	The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2013, 10, 67.	7.2	12
312	Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opinion on Biological Therapy, 2014, 14, 503-513.	3.1	12
313	Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 661-668.	3.0	12
314	Genetic Variation in <scp>WNT9B</scp> Increases Relapse Hazard in Multiple Sclerosis. Annals of Neurology, 2021, 89, 884-894.	5.3	12
315	The Aryl Hydrocarbon Receptorâ€“Dependent TGF-Î±/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	12
316	Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1403-1410.	3.0	12
317	Translational Research in Neurology and Neuroscience 2010. Archives of Neurology, 2010, 67, 1307-15.	4.5	11
318	Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab â€œinfusion groupâ€• Multiple Sclerosis Journal, 2013, 19, 1213-1215.	3.0	11
319	Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients. Journal of Autoimmunity, 2018, 88, 83-90.	6.5	11
320	Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. BMC Medicine, 2020, 18, 298.	5.5	11
321	Is APOE Îµ4 associated with cognitive performance in early MS?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e728.	6.0	11
322	Cryptococcal Meningitis Reported With Fingolimod Treatment. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	11
323	Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability. NeuroImage: Clinical, 2022, 34, 103006.	2.7	11
324	Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. Journal of Neuroimmunology, 2013, 262, 19-26.	2.3	10

#	Article	IF	Citations
325	Immune-directed therapies in MS â€" efficacy and limitations. Nature Reviews Neurology, 2017, 13, 72-74.	10.1	10
326	Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984709.	3.5	10
327	Cerebral vasculitis mimicking migraine with aura in a patient with Crohn's disease. Acta Neurologica Belgica, 2009, 109, 44-8.	1.1	10
328	A new form of axonal pathology in a spinal model of neuromyelitis optica. Brain, 2022, 145, 1726-1742.	7.6	10
329	The role of the Polio Virus Receptor and the Herpesvirus entry mediator B genes for the development of MS. Journal of Neuroimmunology, 2004, 156, 171-177.	2.3	9
330	The antibody response to oligodendrocyte specific protein in multiple sclerosis. Journal of Neuroimmunology, 2010, 221, 81-86.	2.3	9
331	Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologiesâ€"conflicting results?. Multiple Sclerosis Journal, 2015, 21, 537-539.	3.0	9
332	Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e208.	6.0	9
333	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Multiple Sclerosis Journal, 2019, 25, 565-573.	3.0	9
334	Association of peripapillary hyperâ€reflective ovoid masslike structures and disease duration in primary progressive multiple sclerosis. European Journal of Neurology, 2021, 28, .	3.3	9
335	COVID-19-associated Large Vessel Stroke in aÂ28-year-old Patient. Clinical Neuroradiology, 2021, 31, 511-514.	1.9	9
336	No association of three polymorphisms in the alpha-2-macroglobulin and lipoprotein related receptor genes with multiple sclerosis. Journal of Neuroimmunology, 2001, 118, 300-303.	2.3	8
337	Myositis in a patient with large granular leukocyte leukemia. Muscle and Nerve, 2004, 29, 873-877.	2.2	8
338	Specificity and degeneracy: T cell recognition in CNS autoimmunity. Molecular Immunology, 2004, 40, 1057-1061.	2.2	8
339	Surface expression of CXCR4 on circulating CD133+ progenitor cells is associated with plaque instability in subjects with carotid artery stenosis. Journal of Angiogenesis Research, 2009, 1, 10.	2.9	8
340	Mobilization of CD133+ Progenitor Cells in Patients with Acute Cerebral Infarction. PLoS ONE, 2014, 9, e70796.	2.5	8
341	Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene. American Journal of Pathology, 2014, 184, 2420-2429.	3.8	8
342	HLA Genetic Risk Burden in Multiple Sclerosis. JAMA Neurology, 2016, 73, 1500.	9.0	8

#	Article	IF	Citations
343	Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naÃ¨ve notion?. Brain and Behavior, 2019, 9, e01417.	2.2	8
344	Autosomal dominant congenital nystagmus is not linked to 6p12, 7p11, and 15q11 in a German family. American Journal of Ophthalmology, 2004, 138, 439-443.	3.3	7
345	A 32-year-old man with relapsing-progressive brainstem symptoms. Lancet Neurology, The, 2006, 5, 97-102.	10.2	7
346	Revised criteria for neuromyelitis opticaâ€"a new diagnostic standard?. Nature Clinical Practice Neurology, 2007, 3, 132-133.	2.5	7
347	Lack of association between right-to-left shunt and cerebral ischemia after adjustment for gender and age. Journal of Negative Results in BioMedicine, 2008, 7, 7.	1.4	7
348	Short commentary on â€˜a consensus protocol for the standardization of cerebrospinal fluid collection and biobankingâ€™. Multiple Sclerosis Journal, 2010, 16, 129-132.	3.0	7
349	The role of the Epsteinâ€“Barr Virus receptor CD21 in Multiple Sclerosis. Journal of Neuroimmunology, 2012, 242, 47-51.	2.3	7
350	Genetic determinants of the humoral immune response in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e827.	6.0	7
351	Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. Neurological Research and Practice, 2021, 3, 45.	2.0	7
352	Thyroid antibodies in aquaporin-4 antibody positive central nervous system autoimmunity and multiple sclerosis. Clinical Endocrinology, 2011, 75, 271-272.	2.4	6
353	Adult-onset vanishing white matter disease as differential diagnosis of primary progressive multiple sclerosis: A case report. Multiple Sclerosis Journal, 2015, 21, 666-668.	3.0	6
354	Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 124-129.	2.0	6
355	The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis. Acta Neurologica Scandinavica, 2007, 116, 231-234.	2.1	5
356	Sibling disability risk at onset and during disease progression in familial multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1060-1066.	3.0	5
357	Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. Cytokine, 2012, 58, 231-237.	3.2	5
358	Vaccination in B-cellâ€"depleted patients with multiple sclerosis. Neurology, 2020, 95, 613-614.	1.1	5
359	Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1042.	6.0	5
360	Free caspase activity in CSF of patients with dementia. Journal of Neurology, 2009, 256, 1561-1562.	3.6	4

#	Article	IF	Citations
361	Systemic Thrombolysis in Ischemic Stroke After Recent Oral Surgery and Management of Oral Cavity Bleeding. Annals of Emergency Medicine, 2011, 57, 517-519.	0.6	4
362	Daclizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion on Biological Therapy, 2017, 17, 747-753.	3.1	4
363	T1-Weighted Intensity Increase After aÂSingle Administration of aÂLinear Gadolinium-Based Contrast Agent in Multiple Sclerosis. Clinical Neuroradiology, 2021, 31, 235-243.	1.9	4
364	Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. Multiple Sclerosis Journal, 2022, 28, 900-909.	3.0	4
365	Analysis of the Stathmin rs182455 Single Nucleotide Promoter Polymorphism in Patients with Multiple Sclerosis. Journal of Neurogenetics, 2008, 22, 181-186.	1.4	3
366	Should we measure the bioavailability of interferon Î² in vivo in patients with multiple sclerosis?. Nature Reviews Neurology, 2009, 5, 126-127.	10.1	3
367	INTERFERON BETA TREATMENT DOES NOT INDUCE ORGAN-SPECIFIC AUTOANTIBODIES IN MULTIPLE SCLEROSIS. Neurology, 2009, 73, 900-902.	1.1	3
368	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.6	3
369	A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1428-1437.	4.1	3
370	Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG Oligonucleotide. Journal of Neuroinflammation, 2011, 8, 59.	7.2	3
371	Hunting for autoantibodies in multiple sclerosis. Neurology, 2013, 81, 944-945.	1.1	3
372	Spinal cord atrophy in early Huntington's disease. Annals of Clinical and Translational Neurology, 2014, 1, 302-306.	3.7	3
373	Extensive Recruitment of Plasma Blasts to the Cerebrospinal Fluid in Toscana Virus Encephalitis. Open Forum Infectious Diseases, 2015, 2, ofv124.	0.9	3
374	P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica. Neurotherapeutics, 2022, 19, 1603-1616.	4.4	3
375	High Incidence of Postâ€“Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes. Archives of Neurology, 2007, 64, 1055.	4.5	2
376	No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 264-5.	4.5	2
377	Time to talk about timing â€“ when to start, stop and change anti-migratory drugs in MS. Multiple Sclerosis Journal, 2012, 18, 1514-1516.	3.0	2
378	Clinicopathological considerations in acute disseminated encephalomyelitis (ADEM): a fulminant case with favorable outcome. Journal of Neurology, 2012, 259, 753-755.	3.6	2

#	Article	IF	Citations
379	The genetics of natalizumab hypersensitivity. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e52.	6.0	2
380	Intrathecally Expanding B Cell Clones in Herpes Simplex Encephalitis: A Case Report. Neurology and Therapy, 2022, , 1.	3.2	2
381	Association of pregnancies with risk of multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1630-1640.	3.0	2
382	Immunopathogenesis of Multiple Sclerosis. , 2007, , 197-204.		1
383	Natalizumab and primary central nervous system lymphoma revisited. Annals of Neurology, 2011, 69, 1061-1062.	5.3	1
384	Role of statins in the treatment of multiple sclerosis: an update. Neurodegenerative Disease Management, 2011, 1, 109-114.	2.2	1
385	Cognitive impairment as unusual first manifestation in late-onset relapsingâ€“remitting multiple sclerosis. Acta Neurologica Belgica, 2012, 112, 307-309.	1.1	1
386	Spontaneous Cerebrospinal Fluid Leak With Venous Engorgement Mimicking a Contrast-Enhancing Cervical Mass. JAMA Neurology, 2016, 73, 886.	9.0	1
387	CSF Protein Concentration Shows No Correlation With Brain Volume Measures. Frontiers in Neurology, 2019, 10, 463.	2.4	1
388	Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies. Multiple Sclerosis and Related Disorders, 2022, 60, 103728.	2.0	1
389	Immunopathogenesis of Multiple Sclerosis: Overview. , 2007, , 171-187.		0
390	HLA-DRB10401 and HLA-DRB10408 Are Strongly Associated with the Development of Antibodies against Interferon-Î² Therapy in Multiple Sclerosis. American Journal of Human Genetics, 2008, 83, 541.	6.2	0
391	F.36. Introduction of a Cell-based Assay Against Native Aquaporin-4-High Specificity and Sensitivity for Neuromyelitis Optica. Clinical Immunology, 2008, 127, S54-S55.	3.2	0
392	Reply to Dr Pandey. Annals of Neurology, 2013, 73, 148-149.	5.3	0
393	Complex antibody profiling to predict clinical outcome in childhood ADS. Neurology, 2014, 83, 2200-2201.	1.1	0
394	Imaging of pathological effects of aquaporin-4 specific antibodies ex vivo and in vivo. Journal of Neuroimmunology, 2014, 275, 100.	2.3	0
395	Sources and functional significance of IL-6 in shaping autoreactive T cell responses in the peripheral immune compartment and the CNS. Journal of Neuroimmunology, 2014, 275, 152.	2.3	0
396	Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 92, 151.2-151.	1.1	0

#	Article	IF	Citations
397	Plasma Levels of Soluble AÎ²PPÎ² as a Biomarker for Alzheimerâ€™s Disease with Dementia. Journal of Alzheimer's Disease, 2019, 69, 83-90.	2.6	0
398	Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsingâ€“Remitting Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2589-2597.	4.4	0
399	The Role of B Cells in Multiple Sclerosis. , 2013, , 95-114.		0
400	From specificity to degeneracy to molecular mimicry: antigen recognition of human autoreactive and pathogen-specific CD4+ T cells. , 1999, , 21-28.		0
401	Identification of Target Antigens in CNS Inflammation by Protein Array Technique. , 2007, , 137-148.		0